Multiple Genetic Alterations as Resistance Mechanism during Second-Line Lorlatinib for Advanced ALK-Rearranged Lung Adenocarcinoma: A Case Report

Second and third-generation ALK-TKI inhibitors have showed better activity and have replaced crizotinib in most of cases of advanced ALK-rearranged lung adenocarcinoma. The emergence of resistance adversely affects also the activity of these newer drugs; in particular, lorlatinib often shows multipl...

Descripción completa

Detalles Bibliográficos
Autores principales: Catino, Annamaria, Lacalamita, Rosanna, De Summa, Simona, Pesola, Francesco, Tommasi, Stefania, Galetta, Domenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947659/
https://www.ncbi.nlm.nih.gov/pubmed/35328235
http://dx.doi.org/10.3390/diagnostics12030682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947659/
https://www.ncbi.nlm.nih.gov/pubmed/35328235
http://dx.doi.org/10.3390/diagnostics12030682

Ejemplares similares